Genomictree Past Earnings Performance
Past criteria checks 0/6
Genomictree's earnings have been declining at an average annual rate of -1.4%, while the Biotechs industry saw earnings growing at 7.2% annually. Revenues have been growing at an average rate of 26.5% per year.
Key information
-1.4%
Earnings growth rate
2.1%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 26.5% |
| Return on equity | -7.7% |
| Net Margin | -469.2% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Genomictree makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 2,038 | -9,564 | 7,948 | 3,869 |
| 31 Mar 24 | 2,537 | -8,629 | 11,174 | 3,968 |
| 31 Dec 23 | 3,418 | -8,756 | 11,124 | 4,366 |
| 30 Sep 23 | 4,404 | -12,438 | 14,537 | 4,890 |
| 30 Jun 23 | 5,796 | -13,549 | 14,083 | 6,210 |
| 31 Mar 23 | 5,794 | -21,395 | 10,518 | 5,964 |
| 31 Dec 22 | 29,866 | -6,631 | 16,087 | 5,446 |
| 30 Sep 22 | 30,830 | -4,518 | 14,373 | 4,553 |
| 30 Jun 22 | 29,074 | -5,559 | 13,910 | 3,792 |
| 31 Mar 22 | 30,193 | 2,674 | 14,516 | 3,162 |
| 31 Dec 21 | 5,140 | -11,425 | 8,524 | 2,812 |
| 30 Sep 21 | 3,099 | -9,769 | 7,136 | 2,849 |
| 30 Jun 21 | 3,065 | -8,470 | 7,535 | 3,015 |
| 31 Mar 21 | 1,362 | -9,158 | 7,892 | 3,535 |
| 31 Dec 20 | 1,239 | -11,795 | 8,370 | 3,510 |
| 30 Sep 20 | 804 | -15,392 | 10,906 | 3,244 |
| 30 Jun 20 | 691 | -11,125 | 10,770 | 2,758 |
| 31 Mar 20 | 266 | -9,597 | 9,359 | 1,984 |
| 31 Dec 19 | 282 | -10,195 | 7,843 | 1,641 |
| 30 Sep 19 | 269 | -6,097 | 4,481 | 1,457 |
| 31 Dec 18 | 387 | -2,484 | 1,260 | 1,118 |
Quality Earnings: A228760 is currently unprofitable.
Growing Profit Margin: A228760 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A228760 is unprofitable, and losses have increased over the past 5 years at a rate of 1.4% per year.
Accelerating Growth: Unable to compare A228760's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A228760 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (6.1%).
Return on Equity
High ROE: A228760 has a negative Return on Equity (-7.67%), as it is currently unprofitable.